Next Article in Journal
Cytotoxic 1,3-Thiazole and 1,2,4-Thiadiazole Alkaloids from Penicillium oxalicum: Structural Elucidation and Total Synthesis
Previous Article in Journal
Sesquiterpenoids from Chinese Agarwood Induced by Artificial Holing
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 21
Issue 3
10.3390/molecules21030271
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities

by
Hoda H. Fahmy
1,
Nagy M. Khalifa
1,2,*,
Magda M. F. Ismail
3,
Hend M. El-Sahrawy
3 and
Eman S. Nossier
3
1
Department of Therapeutical Chemistry, Pharmaceutical and Drug Industries Division, National Research Centre, Giza 12622, Egypt
2
Pharmaceutical Chemistry Department, Drug Exploration & Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
3
Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754, Egypt
*
Author to whom correspondence should be addressed.
Molecules 2016, 21(3), 271; https://doi.org/10.3390/molecules21030271
Submission received: 3 December 2015 / Revised: 16 February 2016 / Accepted: 19 February 2016 / Published: 26 February 2016
(This article belongs to the Section Bioorganic Chemistry)
Browse Figures
Versions Notes

Abstract

:
With the aim of developing novel antitumor scaffolds, a novel series of polysubstituted pyrazole derivatives linked to different nitrogenous heterocyclic ring systems at the C-4 position were synthesized through different chemical reactions and characterized by means of spectral and elemental analyses and their antiproliferative activity against 60 different human tumor cell lines was validated by the U.S. National Cancer Institute using a two stage process. The in vitro anticancer evaluation revealed that compound 9 showed increased potency toward most human tumor cell lines with GI50MG-MID = 3.59 µM, as compared to the standard drug sorafenib (GI50 MG-MID = 1.90 µM). At the same time, compounds 6a and 7 were selective against the HOP-92 cell line of non-small cell lung cancer with GI50 1.65 and 1.61 µM, respectively.

1. Introduction

The development of new antitumor agents is an important field of scientific activity, due to the toxic side effect problems of recent drugs. Many of the obtainable anticancer agents display unwanted side effects such as reduced bioavailability, toxicity and drug-resistance [1,2,3,4,5]. Incorporation of a pyrazole ring into different heteroaryl ring systems results in significant anticancer activities [6,7,8,9]. Different substituted pyrazole compounds have also been examined for their antiproliferative activities in vitro and antitumor activity in vivo, resulting in promising target products [10,11,12]. On the other hand, compounds containing pyrazole derivatives represent an advantageous choice for the synthesis of compounds with a broad spectrum of pharmacological activities, including anti-inflammatory [13], antibacterial, antifungal [14], inhibition of cyclooxygenase-2 [15], antiangiogenic [16], antipyretic [17], antihypertensive [18], antiplatelet [19], nitric oxide synthase (NOS) inhibitors [20] and anticancer activities [21]. Based on these observations and in continuation of our research on biologically active heterocycles [22,23,24,25], it was of interest to incorporate the 1,2,4-polysubstituted pyrazole ring system into different heteroaryl ring systems in one molecule in an attempt to obtain a new target anticancer agents.

2. Results and Discussion

2.1. Chemistry

The reaction sequences outlined in Scheme 1 and Scheme 2 were used for the synthesis of the target compounds. Application of the Claisen Schmidt condensation on 2-acetylthiophene and 1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazole-4-carboxaldehyde (1) in ethanolic sodium hydroxide solution according to literature methods [26,27] afforded (E)-3-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1-(thiophen-2-yl)prop-2-en-1-one (2), which was used as starting material. Cyclocondensation of the α,β-unsaturated ketone 2 with hydrazine hydrate in absolute ethanol or glacial acetic acid yielded the corresponding pyrazoline derivative 3 and N-acetyl-pyrazoline derivative 4, respectively. On the other hand, heating of 2 with thiosemicarbazide in ethanolic NaOH gave 1-thiocarbamoyl pyrazole derivative 5. In addition, condensation of compound 1 with ethyl cyanoacetate, or ethyl acetoacetate in the presence of guanidine hydrochloride gave 2-amino-5-cyano/acetyl-6-hydroxy-4-aryl pyrimidines 6a,b, respectively (Scheme 1).
Finally, α,β-unsaturated ketone 2 was reacted with hydroxylamine hydrochloride in refluxing ethanol in the presence of sodium hydroxide as alkaline medium to afford the corresponding isoxazoline 7. Treatment of 2 with guanidine sulfate in ethanolic sodium hydroxide gave 2-aminopyrimidine derivative 8, which was reacted with thiourea in the presence of sodium hydroxide to give the corresponding pyrimidine-2-thione derivative 9 (Scheme 2).

2.2. In Vitro Anticancer Screening

The target compounds were selected by the U.S. National Cancer Institute (NCI), for anticancer activity screening. The screening is a two-stage process, beginning with the evaluation at a single dose (10 µM) and the compounds which display significant growth inhibition are then evaluated at five concentration levels. The first screening, where the selected compounds are evaluated at a single dose (10 µM) and the culture is incubated for 48 h, utilizes 60 different human tumor cell lines, representing leukemia, melanoma and cancers of lung, colon, central nervous system (CNS), ovary, kidney, prostate as well as breast.
The percentages of growth of the tested compounds against the full 60-cell line panel are listed in Table 1. The one dose mean graphs of the selected compounds revealed that compounds 6a, 7 and 9 showed increased potency against most human cancer cell lines, so these compounds were selected for further evaluation at five dose concentration levels (0.01–100 µM).Regarding sensitivity against individual cell lines, compound 9 showed potent anticancer activity against all human cancer cell lines with GI50 1.9–5.50 µM. It had the highest selectivity against the non-small cell lung cancer cell line EKVX, with GI50 1.9 µM. At the same time, compounds 6a and 7 showed the highest activity against the cell line HOP-92 belonging to the non-small cell lung cancer class with GI50 1.7 and 1.6 µM, respectively, and against the renal cancer cell line A498 with GI50 1.47 and 1.81 µM, respectively.
Examination of all the ligand structural modifications performed at the 4-position of 1,3,4-trisubstituted pyrazole scaffold to establish the structure activity relationships with anticancer acitivity shows the following results: first, introduction of the pyrimidine-2(1H)-thione moiety in the 4-position of the pyrazole moiety in compound 9 enhanced the potency towards most cancer cell lines. It has GI50 MG-MID = 3.6 µM against all subpanel tumor cell lines, comparable to that of sorafenib (GI50 MG-MID = 1.90 µM. Concerning the pyrazolyl derivative 6a, it was observed that the activity was enhanced in 2-amino-6-oxopyrimidine-5-carbonitrile, which suggests that the polar 6-aminopyrimidine moiety has a role in enhancing anticancer activity (GI50 MG-MID = 5.70 µM), but less so than the 2-mercaptopyrimidine group. Finally, introduction of a 1-carbothioamide to a pyrazole or isoxazoline group substituted on the pyrazole greatly reduces the activity and these compounds showed the least potent activity. The results are presented in Table 1, Table 2, Table 3, Table 4, Table 5 and Table 6.

3. Experimental Section

3.1. General Information

Melting points were measured in open capillary tubes using a Griffin apparatus and are uncorrected. Structures of compounds were confirmed by routine spectrometric analysis. Elemental analyses were carried results were within ±0.4% of the theoretical values. Infrared spectra were recorded on a 435 IR spectrophotometer (Shimadzu Bruker, Tokyo, Japan) using KBr discs. 1H-NMR and 13C-NMR spectra were obtained on a Gemini 500 MHz spectrophotometer (Varian, Polo Alto, Ca, USA) or on a Bruker 500 MHz spectrophotometer, and measured in δ scale using TMS as an internal standard. Mass Spectra were recorded on a 5988 spectrometer (Hewlett Packard, California, USA). Analytical thin layer chromatography (TLC) was performed using silica gel aluminum sheets, 60 F254 (E. Merck, Darmstadt, Germany) for the progress of reactions and visualization with ultraviolet light (UV) at 365 and 254 nm.

3.2. 3-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1-(thiophen-2-yl)prop-2-en-1-one (2)

A mixture of carbaldehyde derivative 1 (0.01 mol) and 2-acetylthiophene (0.01 mol) in of 30% ethanolic solution of NaOH (40 mL) was stirred for 12 h at room temperature. The progress of reaction was monitored by TLC. After completion, the reaction mixture was poured into acidified ice cold water of pH~2. The precipitated solid was filtered, washed with water and recrystallized to afford compound 2 in 87% yield; m.p. 144–146 °C (EtOH); IR (KBr) ν: 3079 (CH-Ar), 1641 (C=O), 1600 (C=C) cm−1; 1H-NMR (DMSO-d6): δ 3.81 (s, 3H, OCH3); 7.00–7.98 (m, 12H, ArH + CH=CH), 8.73 (s,1H, CH of pyrazole) ppm; 13C-NMR (DMSO-d6): δ 55.60, 114.34, 116.62, 117.75, 125.11, 125.95, 127.67, 129.08, 129.81, 131.74, 133.85, 134.47, 135.44, 141.08, 144.32, 151.54, 159.58, 191.96 ppm; MS (EI, 70 eV): m/z (%): 420 (11) [M]+; Anal. Calcd for C23H17ClN2O2S (420.91): C, 65.63; H, 4.07; N, 6.66; Found: C, 65.59; H, 4.16; N, 6.72.

3.3. 1-(3-Chlorophenyl)-4-(4,5-dihydro-3-(thiophen-2-yl)-1H-pyrazol-5-yl)-3-(4-methoxyphenyl)-1H-pyrazole (3)

To a solution of compound 2 (0.01 mol) in ethanol (30 mL) containing a catalytic amount of glacial acetic acid, a solution of hydrazine hydrate (98%, 0.5 mL) was added and the mixture was refluxed for 6 h. The reaction mixture was cooled to room temperature and the precipitated solid was filtered, dried and recrystallization provided compound 3 in 57% yield; m.p. 175–178 °C (EtOH); IR (KBr) ν: 3177 (NH), 1590 (C=C) cm−1; 1H-NMR (DMSO-d6): δ 2.99 (dd, 1H, CH), 3.70 (s, 3H, OCH3), 3.84 (dd, 1H, CH), 5.42 (dd, 1H, CH), 6.39–7.77 (m, 11H, Ar-H), 8.91 (s, 1H, CH of pyrazole), 11.52 (s, 1H, NH D2O exchangeable) ppm; 13C-NMR (DMSO-d6): δ 42.10, 55.61, 60.74, 114.22, 116.78, 117.76, 125.18, 125.90, 126.17, 127.38, 128.67, 129.65, 130.87, 131.26, 134.53, 137.55, 140.98, 151.24, 159.73, 158.76, 161.48 ppm; MS (EI, 70 eV): m/z (%): 434 (18) [M]+; Anal. Calcd for C23H19ClN4OS (434.94): C, 63.51; H, 4.40; N, 12.88; Found: C, 63.59; H, 4.53; N, 12.92.

3.4. 1-(5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4,5-dihydro-3-(thiophen-2yl)pyrazol-1-yl)-ethanone (4)

To a solution of compound 2 (0.01 mol) in glacial acetic acid (20 mL), hydrazine hydrate (0.01 mol) was added and the mixture was refluxed for 3 h. The reaction mixture was cooled to room temperature and the solid formed was filtered off, dried and recrystallized to get compound 4 in 65% yield; m.p. 150–154 °C (EtOH); IR (KBr) ν: 3080 (CH-Ar), 1677 (C=O), 1619 (C=N), 1588 (C=C) cm−1; 1H-NMR (DMSO-d6): 2.43 (s, 3H, COCH3), 3.30 (dd, 1H, CH), 3.81 (s, 3H, OCH3), 3.88 (dd, 1H, CH), 5.57 (dd, 1H, CH), 6.70–7.65 (m, 11H, Ar-H), 9.18 (s, 1H, CH of pyrazole) ppm; 13C-NMR (DMSO-d6): δ 24.01, 43.81, 55.60, 63.87, 114.26, 116.84, 117.62, 125.35, 125.86, 126.10, 127.56, 129.14, 129.78, 130.69, 131.08, 134.41, 137.82, 140.84, 150.39, 155.19, 159.12, 160.92, 168.19 ppm; MS (EI, 70 eV): m/z (%): 476 (43) [M]+; Anal. Calcd for C25H21ClN4O2S (476.98): C, 62.95; H, 4.44; N, 11.75; Found: C, 63.02; H, 4.35; N, 11.81.

3.5. 5-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4,5-dihydro-3-(thiophen-2-yl)-pyrazole-1-carbothioamide (5)

To a mixture of chalcone 2 (0.01 mol) in absolute ethanol (30 mL), sodium hydroxide (1 g, 0.025 mol) was added. The reaction mixture was heated under reflux for 5 h. The contents were reduced, cooled and poured onto crushed ice. The resulting precipitate was collected by filtration and recrystallized to give in 61% yield; m.p. >300 °C (MeOH); IR (KBr) ν: 3407 (NH2), 1658 (C=N), 1523 (C=C), 1078 (C=S) cm−1; 1H-NMR (DMSO-d6): 3.13 (dd, 1H, CH), 3.84 (s, 3H, OCH3), 4.14 (dd, 1H, CH), 5.51 (dd, 1H, CH), 7.14–8.02 (m, 11H, Ar-H), 9.12 (s, 1H, CH of pyrazole), 9.93 (s, 2H, NH2 D2O exchangeable) ppm; 13C-NMR (DMSO-d6): δ 43.14, 55.64, 62.93, 114.33, 116.72, 117.58, 125.37, 125.80, 126.08, 127.54, 128.79, 129.22, 130.65, 131.16, 138.12, 137.82, 140.85, 151.23, 156.19, 159.30, 161.02, 176.55 ppm; MS (EI, 70 eV): m/z (%): 494 (6) [M]+; Anal. Calcd for C24H20ClN5OS2 (494.03): C, 58.35; H, 4.08; N, 14.18; Found: C, 58.27; H, 4.12; N, 14.23.

3.6. 2-Amino-4-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1,6-dihydro-6-oxopyrimidine-5-carbonitrile (6a) and 5-acetyl-2-amino-6-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-pyrimidin-4(3H)-one (6b)

A mixture of compound 1 (0.01 mol), ethyl cyanoacetate or ethyl acetoacetate (0.01 mol) and (5 mL) of 40% ethanolic sodium hydroxide was stirred for 10 min, followed by addition of guanidine hydrochloride (0.01 mol) and the heating continued under refluxed for 3 h. The reaction mixture was diluted with ice-water and the formed precipitate was collected by filtration, washed several times with water, dried and recrystallized to afford the title compounds 6a,b.
2-Amino-4-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-1,6-dihydro-6-oxopyrimidine-5-carbonitrile (6a). Yield 64%; m.p. 144–148 °C (EtOH); IR (KBr) ν: 3341, 3145 (NH2, NH), 2219 (C≡N), 1663 (C=O), 1599 (C=C) cm−1; 1H-NMR (DMSO-d6): 2.85 (s, 2H, NH2 D2O exchangeable), 3.88 (s, 3H, OCH3), 7.03–8.75 (m, 9H, Ar-H and NH D2O exchangeable), 9.20 (s, 1H, CH of pyrazole) ppm; 13C-NMR (DMSO-d6): δ 55.63, 113.75, 115.31, 116.79, 117.77, 123.48, 125.21, 126.4, 127.94, 128.30, 129.82, 130.80, 134.57, 140.89, 155.04, 159.88, 160.60, 164.33, 171.88 ppm; MS (EI, 70 eV): m/z (%): 418 (14) [M]+; Anal. Calcd for C21H15ClN6O2 (418.84): C, 60.22; H, 3.61; N, 20.07; Found: C, 60.26; H, 3.58; N, 20.15.
5-Acetyl-2-amino-6-(1-(3-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)pyrimidin-4-(3H)-one (6b). Yield 68%, m.p. 135–137 °C (EtOH); IR (KBr) ν: 3410, 3152 (NH2,NH), 1675 (C=O), 1589 (C=C) cm−1; 1H-NMR (DMSO-d6): 2.30 (s, 2H, NH2 D2O exchangeable), 2.39 (s, 3H, CH3), 3.86 (s, 3H, OCH3), 6.90–7.96 (m, 9H, Ar-H and NH exchangeable with D2O), 9.14 (s, 1H, CH of pyrazole) ppm; 13C-NMR (DMSO-d6): δ 24.38, 55.60, 113.72, 115.94, 116.85, 117.73, 125.10, 126.01, 128.36, 130.76, 132.95, 134.47, 141.05, 151.14, 154.78, 159.60, 160.82, 164.21, 165.38, 182.70 ppm; MS (EI, 70 eV): m/z (%): 435 (7) [M]+; Anal. Calcd for C22H18ClN5O3 (435.86): C, 60.62; H, 4.16; N, 16.07; Found: C, 60.59; H, 4.11; N, 16.12.

3.7. 1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-4-(3-(thiophen-2-yl)isoxazol-5-yl)-1H-pyrazole (7)

A mixture of compounds 2 (0.01 mol) and hydroxylamine hydrochloride (0.01 mol) in ethanol (30 mL) containing sodium hydroxide solution (0.5 g NaOH in 0.5 mL water) was refluxed for 3 h. The reaction mixture was poured onto ice-water, neutralized with drops of conc. Hydrochloric acid and the solid precipitate formed filtered off, washed with water and recrystallized to yield the desired compound 7 in 73% yield; m.p. >300 °C (EtOH); IR (KBr) ν: 3064 (CH-Ar), 1601 (C=C) cm−1; 1H-NMR (DMSO-d6): 3.99 (s, 3H, OCH3), 7.30 (d, 2H, H J = 20), 7.60 (d, 1H, CH); 7.75–8.45 (m, 10H, Ar-H), 9.15 (s, 1H, CH of pyrazole) ppm; 13C-NMR (DMSO-d6): δ 43.19, 55.61, 73.10, 114.38, 116.72, 117.68, 125.68, 125.84, 126.10, 127.43, 129.07, 129.57, 130.81, 131.29, 134.47, 138.21, 140.85, 151.20, 154.63, 160.92, 162.89 ppm; MS (EI, 70 eV): m/z (%): 433 (12) [M]+; Anal. Calcd for C23H16ClN3O2S (433.91): C, 63.66; H, 3.72; N, 9.68; Found: C, 63.74; H, 3.79; N, 9.71.

3.8. 4-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-6-(thiophen-2-yl)pyrimidin-2-amine (8)

An aqueous solution 5 mL of 40% sodium hydroxide was added gradually during a period of 3 h to a mixture of chalcone 2 (0.01 mol) and guanidine sulfate (0.01 mol) in ethanol (25 mL). The reaction mixture was refluxed for 5 h and the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was poured onto ice-cold water and the solid product formed was collected by filtration, washed with water then recrystallized to get compound 8 in 67% yield; m.p. >300 °C (MeOH); IR (KBr) ν: 3347 (NH2); 1632 (C=N); 1589 (C=C) cm−1; 1H-NMR (DMSO-d6): 3.80 (s, 3H, OCH3), 6.68-8.08 (t, 12H, Ar-H), 8.93 (s,1H, CH of pyrazole), 10.18 (s, 2H, NH2 D2O exchangeable) ppm; 13C-NMR (DMSO-d6): δ 55.64, 82.10, 114.31, 116.80, 117.59, 125.30, 125.78, 126.09, 127.41, 128.67, 129.48, 130.79, 131.16, 134.49, 139.86, 141.05, 150.88, 152.10, 160.37, 164.21, 166.58, 164.25 ppm; Anal. Calcd for C24H18ClN5OS (459.95): C, 62.67; H, 3.94; N, 15.23; Found: C, 62.63; H, 3.88; N, 15.29.

3.9. 6-(1-(3-Chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-4-yl)-4-(thiophen-2-yl)pyrimidine-2-(1H)-thione (9)

A solution of the chalcone 2 (0.01 mol), thiourea (0.01 mol) and sodium hydroxide (0.1 g) in absolute ethanol (30 mL) was refluxed for 6 h. The reaction mixture was concentrated under vacuum, cooled and neutralized with dilute HCl. The formed product was filtered off, washed with water and recrystallized to get compound 9 in 76% yield; m.p. >300 °C (MeOH); IR (KBr) ν: 3422 (NH), 1595 (C=C), 1176 (C=S) cm−1; 1H-NMR (DMSO-d6): 3.82 (s, 3H, OCH3), 6.90–8.60 (m, 12H, Ar-H), 9.20 (s, 1H, CH of pyrazole), 9.95 (s, 1H, NH D2O exchangeable) ppm; 13C-NMR (DMSO-d6): δ 55.63, 104.56, 113.82, 115.89, 117.66, 125.38, 125.70, 126.03, 127.38, 128.34, 129.45, 130.77, 131.09, 134.42, 138.17, 140.95, 150.76, 157.21, 160.85, 161.80, 162.46, 184.33 ppm; MS (EI, 70 eV): 477 (8) [M]+; Anal. Calcd for C24H17ClN4OS2 (477): C, 60.43; H, 3.59; N, 11.75; Found: C, 60.38; H, 3.66; N, 11.82.

3.10. Measurement of Anticancer Activity

The experimental method used in anticancer screening has been adopted by U.S. National Cancer Institute according to reported standard procedure [28,29,30].

4. Conclusions

In summary, we have synthesized a series of novel pyrazole derivatives incorporated different heteroaryl ring systems in one molecule and evaluated these compounds for their anticancer activities against different 60 human cancer cell lines representing leukemia, melanoma and cancers of lung, colon, brain, ovary, breast, prostate and kidney cancer using a two-stage process. The pyrimidine-2(1H)-thione derivative 9 showed good anticancer activity with (GI50 MG-MID = 3.59 µM) compared to the standard drug sorafenib. The structures of the new compounds were elucidated using spectroscopic and elemental analysis.

Acknowledgments

The project was financially supported by King Saud University, Vice Deanship of Research Chairs.

Author Contributions

The listed authors contributed to this work as described in the following. Hoda H. Fahmy gave the concepts of the work, interpreted the results and prepared the manuscript, Eman S. Nossier, carried out the synthetic work, interpreted the results and prepared the manuscript and Nagy M. Khalifa, Magda M. F. Ismail and Hend M. El-Sahrawy interpreted the results and cooperated in the preparation of the manuscript. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. Cancer J. Clin. 2008, 58, 71–96. [Google Scholar] [CrossRef] [PubMed]
  2. Eckhardt, S. Recent progress in the development of anticancer agents. Curr. Med. Chem. Anticancer Agents 2002, 2, 419–439. [Google Scholar] [CrossRef] [PubMed]
  3. Altmann, K.H. Microtubule-stabilizing agents: A growing class of important anticancer drugs. Curr. Opin. Chem. Biol. 2001, 5, 424–431. [Google Scholar] [CrossRef]
  4. Wartmann, M.; Altmann, K.H. The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anticancer Agents 2002, 2, 1231–1248. [Google Scholar] [CrossRef]
  5. O’Dwyer, M.E.; Druker, B.J. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr. Cancer Drug Targets 2001, 1, 49–57. [Google Scholar] [CrossRef] [PubMed]
  6. Xia, Y.; Dong, Z.W.; Zhao, B.X.; Ge, X.; Meng, N.; Shin, D.S.; Miao, J.Y. Synthesis and structure-activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide derivatives as potential agents against A549 lung cancer cells. Bioorg. Med. Chem. 2007, 15, 6893–6899. [Google Scholar] [CrossRef] [PubMed]
  7. Farghaly, A.R. Synthesis of some new indole derivatives containing pyrazoles with potential antitumor activity. ARKIVOC 2010, 11, 177–187. [Google Scholar]
  8. El-Zahar, M.I.; EL-Karim, S.A.; Haiba, M.E.; Khedr, M.A. Synthesis, antitumor activity and molecular docking study of novel benzofuran-2-yl pyrazole pyrimidine derivatives. Acta Pol. Pharm. Drug. Res. 2011, 68, 357–373. [Google Scholar]
  9. Kalirajan, R.; Rathore, L.; Jubie, S.; Gowramma, B.; Gomathy, S.; Sankar, S. Microwave assisted synthesis of some novel pyrazole substituted benzimidazoles and evaluation of their biological activities. Indian J. Chem. 2011, 50B, 1794–1799. [Google Scholar] [CrossRef]
  10. Perchellet, E.M.; Ward, M.M.; Skaltsounis, A.L.; Kostakis, I.K.; Pouli, N.; Marakos, P.; Perchellet, J.H. Antiproliferative and proapoptotic activities of pyranoxanthenones, pyranothioxanthenones and their pyrazole-fused derivatives in HL-60 cells. Anticancer Res. 2006, 26, 2791–2804. [Google Scholar] [PubMed]
  11. Insuasty, B.; Tigreros, A.; Orozco, F.; Quiroga, J.; Abonia, R.; Nogueras, M.; Sanchez, A.; Cobo, J. Synthesis of novel pyrazolic analogues of chalcones and their 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole derivatives as potential antitumor agents. Bioorg. Med. Chem. 2010, 18, 4965–4974. [Google Scholar] [CrossRef] [PubMed]
  12. Labbozzetta, M.; Baruchello, R.; Marchetti, P.; Gueli, M.C.; Poma, P.; Notarbartolo, M.; Simoni, D.; D’Alessandro, N. Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin; implications for their antitumor and chemosensitizing activities. Chem. Biol. Interact. 2009, 181, 29–36. [Google Scholar] [CrossRef] [PubMed]
  13. Szabo, G.; Fischer, J.; Kis-Varga, A.; Gyires, K. New celecoxib derivatives as anti-inflammatory agents. J. Med. Chem. 2008, 51, 142–147. [Google Scholar] [CrossRef] [PubMed]
  14. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Terauchi, H.; Kawasaki, M.; Wachi, M.; Yamagishi, J. Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl]pyrazoles. Bioorg. Med. Chem. Lett. 2005, 15, 4299–4303. [Google Scholar] [CrossRef] [PubMed]
  15. Rida, S.M.; Saudi, M.N.S.; Youssef, A.M.; Halim, M.A. Synthesis and biological evaluation of the pyrazole class of cyclooxygenase-2-inhibitors. Lett. Org. Chem. 2009, 6, 282–288. [Google Scholar] [CrossRef]
  16. Abadi, A.H.; Abdel Haleem, A.; Hassan, G.S. Synthesis of novel 1,3,4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents. Chem. Pharm. Bul. 2003, 51, 838–844. [Google Scholar] [CrossRef]
  17. Sridhar, S.; Parsad, R.Y. Synthesis and Analgesic Studies of Some New 2-pyrazolines. Eur. J. Chem. 2012, 9, 1810–1815. [Google Scholar] [CrossRef]
  18. Turan-Zitouni, G.; Chevallet, P.; Kilic, F.S.; Erol, K. Synthesis of some thiazolyl-pyrazoline derivatives and preliminary investigation of their hypotensive activity. Eur. J. Med. Chem. 2000, 35, 635–641. [Google Scholar] [CrossRef]
  19. Zhou, S.; Ren, J.; Liu, M.; Ren, L.; Liu, Y.; Gong, P. Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents. Bioorg. Chem. 2014, 57, 30–42. [Google Scholar] [CrossRef] [PubMed]
  20. Kumar, S.; Bawa, S.; Drabu, S.; Kumar, R.; Gupta, H. Biological activities of pyrazoline derivatives—A recent development. Drug Discov. 2009, 4, 154–163. [Google Scholar] [CrossRef]
  21. Havrylyuk, D.; Zimenkovsky, B.; Vasylenko, O.; Zaprutko, L.; Gzella, A.; Lesyk, R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur. J. Med. Chem. 2009, 44, 1396–1404. [Google Scholar] [CrossRef] [PubMed]
  22. Khalifa, N.M.; Al-Omar, M.A.; Amr, A.E.; Baiuomy, A.R.; Abdel Rahman, R.F. Synthesis and biological evaluation of some novel fused thiazolo[3,2-a]pyrimidines as potential analgesic and antiinflammatory agents. Russ. J. Bioorg. Chem. 2015, 41, 192–201. [Google Scholar] [CrossRef]
  23. Eweas, A.F.; Khalifa, N.M.; Ismail, N.S.; Al-Omar, M.A.; Soliman, A.M. Synthesis, molecular docking of novel 1,8-naphthyridine derivatives and their cytotoxic activity against HepG2 cell lines. Med Chem Res. 2014, 23, 76–86. [Google Scholar] [CrossRef]
  24. Almutairi, M.S.; Hegazy, G.H.; Haiba, M.E.; Ali, H.I.; Khalifa, N.M.; Soliman, A.M. Synthesis, Docking and Biological Activities of Novel Hybrids Celecoxib and Anthraquinone Analogs as Potent Cytotoxic Agents. Int. J. Mol. Sci. 2014, 15, 22580–22603. [Google Scholar] [CrossRef] [PubMed]
  25. Haiba, M.E.; Al-Abdullah, E.S.; Edrees, M.M.; Khalifa, N.M. Synthesis and characterization of some substituted 3,4-dihydronaphthalene derivatives through different enaminones as potent cytotoxic agents. Drug Res. 2015, 65, 9–17. [Google Scholar]
  26. Babasaheb, P.B.; Shrikant, S.G.; Ragini, G.B.; Jalinder, V.T.; Chandrahas, N.K. Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. Bioorg. Med. Chem. 2010, 18, 1364–1370. [Google Scholar]
  27. Syam, S.; Abdelwahab, S.I.; Al-Mamary, M.A.; Mohan, S. Synthesis of chalcones with anticancer activities. Molecules 2012, 17, 6179–6195. [Google Scholar] [CrossRef] [PubMed]
  28. Alley, M.C.; Scudiero, D.A.; Monks, P.A.; Hursey, M.L.; Fine, M.J.; Czerwinski, D.L.; Abbott, B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589–601. [Google Scholar] [PubMed]
  29. Grever, M.R.; Schepartz, S.A.; Chabner, B.A. The National Cancer Institute: Cancer drug discovery and development program. Semin. Oncol. 1992, 19, 622–638. [Google Scholar] [PubMed]
  30. Boyd, M.R.; Paull, K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91–109. [Google Scholar] [CrossRef]
  • Sample Availability: Samples of all the compounds are available from the authors.
Molecules 21 00271 g001 550
Scheme 1. Synthetic route for trisubstituted pyrazole compounds 2–6.
Scheme 1. Synthetic route for trisubstituted pyrazole compounds 2–6.
Molecules 21 00271 g001
Reagents and Conditions: (i) ethanol/NaOH/rt./12 h, 87%; (ii) N2H4.H2O/ethanol/reflux/6 h, 57%; (iii) N2H4∙H2O/AcOH/reflux/3h, 65%; (iv) NH2NHCSNH2/ethanol/NaOH/reflux/5 h, 61%; (v) NC-CH2COOEt or CH3COCH2COOEt, H2N-C(NH)-NH2∙HCl/ethanol/NaOH/reflux 3 h, 64–68%.
Molecules 21 00271 g002 550
Scheme 2. Synthetic route for trisubstituted pyrazole compounds 7–9.
Scheme 2. Synthetic route for trisubstituted pyrazole compounds 7–9.
Molecules 21 00271 g002
Reagents and Conditions: (i) NH2OH∙HCl/ethanol/NaOH/reflux/3 h, 73%; (ii) H2N-C(NH)-NH2∙H2SO4/ethanol/NaOH reflux/5 h, 67%; (iii) NH2CSNH2/ethanol/NaOH/reflux/6 h, 76%.
Table
Table 1. The mean growth percent of compounds 2, 3, 4, 6a, 6b, 7, 8 and 9.
Table 1. The mean growth percent of compounds 2, 3, 4, 6a, 6b, 7, 8 and 9.
Cpd. No.NSC No.Mean Growth Percent
2762925/195.56
3763580/1102.40
4763581/198.43
6a762930/167.27
6b762931/176.45
7762927/147.83
8762928/199.26
9762929/149.53
Table
Table 2. GI50 (μM) of five-dose screening results of compounds 6a, 7 and 9.
Table 2. GI50 (μM) of five-dose screening results of compounds 6a, 7 and 9.
Subpanel Cell Lines
GI50
Cell lines6a79
Leukemia
CCRF-CEM3.653.842.80
HL-60(TB)3.964.733.49
K-5623.453.432.91
MOLT-44.802.963.03
RPMI-82265.635.332.42
SR3.733.034.00
Non-Small Cell Lung Cancer
A549/ATCC5.133.562.29
EKVX3.292.071.93
HOP-6210.113.907.14
HOP-921.651.612.20
NCI-H2266.234.113.16
NCI-H235.443.823.43
NCI-H4606.003.423.01
NCI-H5223.114.272.54
NCI-H322M
Colon Cancer
COLO 2057.653.212.35
HCC-29985.873.474.03
HCT-1164.353.032.38
HCT-155.074.483.69
HT294.293.853.82
KM123.842.983.67
SW-6204.384.353.79
CNS Cancer
SF-2685.864.944.52
SF-2952.362.702.07
SF-5396.597.474.70
SNB-194.586.084.93
SNB-752.883.523.49
U2513.663.612.60
Melanoma
LOX IMVI4.023.043.56
MALME-3M5.832.603.49
M143.253.302.81
MDA-MB-4352.163.263.13
SK-MEL-23.943.342.87
SK-MEL-284.984.933.93
SK-MEL-54.074.742.93
UACC-2575.693.073.06
UACC-623.333.552.78
Ovarian Cancer
IGROV13.0143.61
OVCAR-33.385.073.04
OVCAR-47.714.483.47
OVCAR-514.607.636.38
OVCAR-810.104.043.15
NCI/ADR-RES3.334.014.77
SK-OV-36.568.895.91
Renal Cancer
786-04.653.394.18
A4981.471.813.01
ACHN9.924.394.05
CAKI-12.522.053.03
RXF 3934.513.493.76
SN12C6.413.483.92
TK-1013.505.214.55
UO-312.942.562.82
Prostate Cancer
PC-36.303.23.09
DU-14517.97.085.49
Breast Cancer
MCF73.543.533.02
MDA-MB-231/ATCC3.393.083.52
HS 578T3.554.424.26
BT-5493.554.993.18
T-47D6.053.864.16
MDA-MB-4682.122.682.57
GI50: (growth inhibitory activity) the drug concentration that reduces cellular growth by 50%.
Table
Table 3. TGI (μM) of five-dose screening results of compounds 6a, 7 and 9.
Table 3. TGI (μM) of five-dose screening results of compounds 6a, 7 and 9.
Subpanel Cell Lines
TGI
Cell lines6a79
Leukemia
CCRF-CEM33.80>100>100
HL-60(TB)14.2038.3013.20
K-562>100>100>100
MOLT-439.8019.5025.20
RPMI-822655.5061.9010.90
SR21.2012.1031.90
Non-Small Cell Lung Cancer
A549/ATCC50.8024.5016.50
EKVX35.4013.5021.70
HOP-6226.2028.1022.10
HOP-9212.208.1310.80
NCI-H22670.30030.3054.40
NCI-H2346.2020.8016.20
NCI-H46027.7016.6011.00
NCI-H5229.8018.408.86
NCI-H322M
COLO 20520.907.245.59
HCC-299824.9014.6016.40
HCT-11616.2012.7011.20
HCT-15>10032.90>100
HT2920.0015.1013.00
KM1215.2011.1014.40
SW-62034.2022.6022.30
CNS Cancer
SF-26835.447.1073.60
SF-2959.2213.207.09
SF-53932.236.6019.70
SNB-19100>100>100
SNB-7521.134.7025.60
U25118.815.4012.40
Melanoma
LOX IMVI20.1010.9013.80
MALME-3M40.6010.6015.80
M1434.0017.1014.00
MDA-MB-4355.4817.3019.00
SK-MEL-215.8010.906.90
SK-MEL-2827.9017.8015.70
SK-MEL-515.9017.3010.90
UACC-25747.3015.1018.00
UACC-6215.4020.0019.20
Ovarian Cancer
IGROV118.1016.2015.30
OVCAR-310.0025.009.42
OVCAR-461.9036.40>100
OVCAR-551.4074.10>100
OVCAR-860.3036.00>100
NCI/ADR-RES15.9038.1041.80
SK-OV-330.7044.1036.80
Renal Cancer
786-033.50>100>100
A4986.7514.6017.00
ACHN>100>100>100
CAKI-115.306.028.68
RXF 39322.4020.1019.50
SN12C>10018.70>100
TK-1053.9043.8032.80
UO-3147.8011.8026.50
Prostate Cancer
PC-3>10036.90>100
DU-14570.1035.8072.50
Breast Cancer
MCF728.5016.9033.40
MDA-MB-231/ATCC53.3016.9026.00
HS 578T40.3045.50>100
BT-54922.4021.3015.90
T-47D32.2025.3034.60
MDA-MB-4686.4312.309.91
TGI: the drug concentration required for total growth inhibition.
Table
Table 4. LC50 (μM) of five-dose screening results of compounds 6a, 7 and 9.
Table 4. LC50 (μM) of five-dose screening results of compounds 6a, 7 and 9.
Subpanel Cell Lines
LC50
Cell lines6a79
Leukemia
CCRF-CEM>100>100>100
HL-60(TB)>100>100>100
K-562>100>100>100
MOLT-4>100>100>100
RPMI-8226>100>100>100
SR>100>100>100
Non-Small Cell Lung Cancer
A549/ATCC>100>100>100
EKVX>100>100>100
HOP-6267.8056.9059.80
HOP-92>100>10083.20
NCI-H226>100>100>100
NCI-H23>100>100>100
NCI-H460>100>10052.00
NCI-H522>10093.50>100
NCI-H322M
Colon Cancer
COLO 205>5024.7040.00
HCC-2998>10064.7096.00
HCT-11646.0040.6033.80
HCT-15>100>100>100
HT29>100>10046.90
KM1249.7084.6049.30
SW-620>100>100>100
CNS Cancer
SF-268>100>100>100
SF-29584.70>10061.30
SF-539>100>10082.30
SNB-19>100>100>100
SNB-75>100>100>100
U25182.8049.5038.30
Melanoma
LOX IMVI74.1054.9045.20
MALME-3M>10060.0097.20
M14>10084.1090.10
MDA-MB-435>100>100>100
SK-MEL-299.1066.8035.60
SK-MEL-28>10052.4058.80
SK-MEL-551.3047.5041.90
UACC-257>100>100>100
UACC-6253.3065.7071.60
Ovarian Cancer
IGROV1>10071.2073.80
OVCAR-360.30>10035.90
OVCAR-4>100>100>100
OVCAR-5>100100>100
OVCAR-8>100>100>100
NCI/ADR-RES>100>100>100
SK-OV-3>100>100>100
Renal Cancer
786-0>100>100>100
A498>10045.2073.20
ACHN>100>100>100
CAKI-1>10075.90>100
RXF 393>100>100>100
SN12C>100>100>100
TK-10>100>100>100
UO-31>100>100>100
Prostate Cancer
PC-3>100>100>100
DU-145>100>100>100
Breast Cancer
MCF7>10083.60>100
MDA-MB-231/ATCC>100>100>100
HS 578T>100>100>100
BT-549>10066.30>100
T-47D>100>100>100
MDA-MB-468>100>100>100
LC50: the drug concentration required for killing 50% of cells.
Table
Table 5. Median growth inhibitory concentrations (GI50, μM) of in vitro subpanel tumor cell lines and GI50 (μM) full panel mean-graph mid-points (MG-MID) of compounds 6a, 7 and 9 in comparison with sorafenib.
Table 5. Median growth inhibitory concentrations (GI50, μM) of in vitro subpanel tumor cell lines and GI50 (μM) full panel mean-graph mid-points (MG-MID) of compounds 6a, 7 and 9 in comparison with sorafenib.
Subpanel Tumor Cell Lines
Cpd. No.LeukemiaLungColonCNSMelanomaOvarianRenalProstateBreastGI50 MG-MID
6a4.25.15.14.34.17.05.712.13.75.7
73.94.63.64.73.55.53.35.13.84.2
93.13.23.43.73.24.33.74.33.53.6
Sorafenib1.9
Table
Table 6. Selectivity ratios for compounds 6a, 7 and 9 towards the nine tumor cell lines.
Table 6. Selectivity ratios for compounds 6a, 7 and 9 towards the nine tumor cell lines.
Subpanel Tumor Cell Lines
Cpd. No.LeukemiaLungColonCNSMelanomaOvarianRenalProstateBreast
6a1.41.11.11.31.40.81.00.51.5
71.10.91.20.91.20.81.30.81.1
91.21.11.11.01.10.81.00.81.0

Share and Cite

MDPI and ACS Style

Fahmy, H.H.; Khalifa, N.M.; Ismail, M.M.F.; El-Sahrawy, H.M.; Nossier, E.S. Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities. Molecules 2016, 21, 271. https://doi.org/10.3390/molecules21030271

AMA Style

Fahmy HH, Khalifa NM, Ismail MMF, El-Sahrawy HM, Nossier ES. Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities. Molecules. 2016; 21(3):271. https://doi.org/10.3390/molecules21030271

Chicago/Turabian Style

Fahmy, Hoda H., Nagy M. Khalifa, Magda M. F. Ismail, Hend M. El-Sahrawy, and Eman S. Nossier. 2016. "Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities" Molecules 21, no. 3: 271. https://doi.org/10.3390/molecules21030271

Article Metrics

Back to TopTop